Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lupus Nephritis AND Systemic Lupus Erythematosus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Lupus Nephritis AND Systemic Lupus Erythematosus. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-006544-26 Sponsor Protocol Number: INTONATE Start Date*: 2022-12-23
    Sponsor Name:A.S.L. TO 2
    Full Title: INTONATE INtensified procol for lupus nephritis with riTuximab and nO maintaiNAnce ThErapy
    Medical condition: lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004047-86 Sponsor Protocol Number: AIS-A03 Start Date*: Information not available in EudraCT
    Sponsor Name:Alpine Immune Sciences, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10042946 Systemic lupus erythematosus rash PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    20.1 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    20.0 10022891 - Investigations 10067658 Systemic lupus erythematosus disease activity index decreased PT
    20.1 10022891 - Investigations 10067659 Systemic lupus erythematosus disease activity index abnormal PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10080670 Systemic lupus erythematosus reactivation LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10073694 Lupus pleurisy PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10040968 SLE arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001796-14 Sponsor Protocol Number: CYTB323G12101 Start Date*: 2023-03-20
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
    Medical condition: Systemic Lupus Erythematosus Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003137-19 Sponsor Protocol Number: M-2022-398 Start Date*: 2023-05-30
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: An open-label phase I/IIa, multicenter, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE
    Medical condition: Adult patients with refractory active systemic lupus erythematosus (SLE) with organ involvement
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005543-14 Sponsor Protocol Number: CTU/2013/096 Start Date*: 2016-07-19
    Sponsor Name:University College London
    Full Title: Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-000674-73 Sponsor Protocol Number: LJP 394-90-14 Start Date*: 2006-08-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOS...
    Medical condition: Systemic lupus erythematosus patients with a history of renal disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042945 Systemic lupus erythematosus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000488-42 Sponsor Protocol Number: Teng-001 Start Date*: 2014-05-12
    Sponsor Name:Leiden University Medical Center
    Full Title: The SYNBioSe Study A proof-of-concept study involving synergetic B-cell imunnomodulation in patients with refractory systemic lupus erythematosus
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004575-37 Sponsor Protocol Number: IM101075 Start Date*: 2007-04-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate...
    Medical condition: IMMUNOSUPPRESSION FOR DISEASE, NOS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2019-000638-20 Sponsor Protocol Number: M19-130 Start Date*: 2020-01-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic ...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) NL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000594-69 Sponsor Protocol Number: 211LE202 Start Date*: 2014-06-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001392-21 Sponsor Protocol Number: P018.087 Start Date*: 2018-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    21.1 100000004859 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020968-38 Sponsor Protocol Number: CNTO136LUN2001 Start Date*: 2011-03-17
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lup...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005772-19 Sponsor Protocol Number: CAIN457Q12301E1 Start Date*: 2022-07-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) SK (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018329-20 Sponsor Protocol Number: LN-LAQ-201 Start Date*: 2010-05-07
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combinati...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025140 Lupus nephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003201-34 Sponsor Protocol Number: U2970g Start Date*: 2016-08-07
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
    Medical condition: ISN/RPS 2003 Class III or IV Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000243-80 Sponsor Protocol Number: MSV_LE Start Date*: 2022-05-26
    Sponsor Name:Hospital Universitario Rio Hortega
    Full Title: PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF MESENCHYMAL CELLS (MSV-allo®) IN THE TREATMENT OF LUPUS NEPHRITIS.
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004518-15 Sponsor Protocol Number: 28113 Start Date*: 2008-08-05
    Sponsor Name:Merck Serono International
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025140 Lupus nephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000305-23 Sponsor Protocol Number: BOS161721-02 Start Date*: 2019-03-20
    Sponsor Name:Boston Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-023396-25 Sponsor Protocol Number: SM101-201-sle-10 Start Date*: 2011-09-22
    Sponsor Name:SuppreMol GmbH
    Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001619-35 Sponsor Protocol Number: P1200_41 Start Date*: 2017-06-01
    Sponsor Name:Cliniques Universitaires Saint-lus, Université catholique de Louvain
    Full Title: Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:30:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA